Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis
<p>Abstract</p> <p>Background</p> <p>Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-03-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/2/1/13 |